Concepedia
Statistics
Publications
57
Citations
4.2K
H-Index
33
Active since
1989
Affiliations
AstraZeneca (United States)(Current)
AstraZeneca (United Kingdom)
University of Oxford
AstraZeneca (Sweden)
Ionis Pharmaceuticals (United States)
Paul D. Lyne is an author at AstraZeneca (United States) specializing in pharmacology, drug discovery, and medicinal chemistry.
Publications per year
1989–2022
Accurate Prediction of the Relative Potencies of Members of a Series of Kinase Inhibitors Using Molecular Docking and MM-GBSA Scoring
Paul D. Lyne, Michelle L. Lamb, Jamal Saeh · Journal of Medicinal Chemistry · 2006 · 705 citations · Full text
Pharmacy, Medicinal Chemistry, Pharmacology +17
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial
Matthew J. Reilley, Patricia McCoon, Carl Cook et al. · Journal for ImmunoTherapy of Cancer · 2018 · 288 citations · Full text
Medicine, Oncology, Pharmacotherapy +13
AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia
Erika Krasnickas Keeton, Kristen McEachern, Keith Dillman et al. · Blood · 2013 · 247 citations
Medicine, Medicinal Chemistry, Pharmacology +11
On Evaluating Molecular-Docking Methods for Pose Prediction and Enrichment Factors
Hongming Chen, Paul D. Lyne, Fabrizio Giordanetto et al. · Journal of Chemical Information and Modeling · 2005 · 230 citations
Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS
Sarah J. Ross, Alexey S. Revenko, Lyndsey Hanson et al. · Science Translational Medicine · 2017 · 182 citations
Medicine, Oncology, Pharmacology +16
1–5 of 57